Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.

Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA.

Clin Transl Sci. 2019 Mar 28. doi: 10.1111/cts.12634. [Epub ahead of print]

PMID:
30920122
2.

Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients.

Bursi R, Piana C, Grevel J, Huntjens D, Boesl I.

Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):801-814. doi: 10.1007/s13318-017-0400-7.

3.

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.

Lin SM, Lu SN, Chen PT, Jeng LB, Chen SC, Hu CT, Yang SS, Le Berre MA, Liu X, Mitchell DY, Prins K, Grevel J, Peña CA, Meinhardt G.

Hepatol Int. 2017 Mar;11(2):199-208. doi: 10.1007/s12072-016-9774-x. Epub 2016 Dec 1.

4.

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

Mentré F, Chenel M, Comets E, Grevel J, Hooker A, Karlsson MO, Lavielle M, Gueorguieva I.

CPT Pharmacometrics Syst Pharmacol. 2013 Jun 5;2:e46. doi: 10.1038/psp.2013.19. No abstract available.

5.

Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity.

Serino F, Grevel J, Napoli KL, Kahan BD, Strobel HW.

Transplant Proc. 1994 Oct;26(5):2916-7. No abstract available.

PMID:
7940922
6.

Abbreviated three-point kinetic profile in the 12-hour area under the curve for pharmacokinetic monitoring of cyclosporine.

Serino F, Citterio F, Pozzetto U, Grevel J, Castagneto M.

Transplant Proc. 1994 Oct;26(5):2807-8. No abstract available.

PMID:
7940882
7.

Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.

Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K.

Pharm Res. 1994 Feb;11(2):301-4.

PMID:
8165192
8.

Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lücker PW, Kutz K.

Pharm Res. 1994 Jan;11(1):151-5.

PMID:
8140046
10.
11.

Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes.

Ahmed SS, Strobel HW, Napoli KL, Grevel J.

J Pharmacol Exp Ther. 1993 Jun;265(3):1047-54.

PMID:
7685382
12.

Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition.

Serino F, Grevel J, Napoli KL, Kahan BD, Strobel HW.

Mol Cell Biochem. 1993 May 26;122(2):101-12.

PMID:
8232241
13.

Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Grevel J.

Clin Pharmacokinet. 1992 Nov;23(5):380-90. Review.

PMID:
1478005
14.

Pharmacokinetic strategies for cyclosporin therapy in organ transplantation.

Kahan BD, Welsh M, Knight R, Katz S, Lewis R, Grevel J, Van Buren CT.

J Autoimmun. 1992 Apr;5 Suppl A:333-41.

PMID:
1503629
15.

The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation.

Kahan BD, Welsh M, Rutzky L, Lewis R, Knight R, Katz S, Napoli K, Grevel J, Van Buren CT.

Transplantation. 1992 Feb;53(2):345-51.

PMID:
1738928
16.
17.

Area under the curve monitoring of cyclosporine therapy: the early posttransplant period.

Grevel J, Kahan BD.

Ther Drug Monit. 1991 Mar;13(2):89-95.

PMID:
2053129
18.

Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.

Grevel J, Napoli KL, Welsh MS, Atkinson NE, Kahan BD.

Pharm Res. 1991 Feb;8(2):278-81.

PMID:
2023881
19.

Preemptive transplantation--an analysis of benefits and hazards in 85 cases.

Katz SM, Kerman RH, Golden D, Grevel J, Camel S, Lewis RM, Van Buren CT, Kahan BD.

Transplantation. 1991 Feb;51(2):351-5.

PMID:
1825243
20.

Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

Tredger JM, Grevel J, Naoumov N, Steward CM, Niven AA, Whiting B, Williams R.

Eur J Clin Pharmacol. 1991;40(5):513-9.

PMID:
1884727
21.

Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A.

Clin Chem. 1990 Aug;36(8 Pt 1):1510-6. Review.

22.

Covariables in cyclosporine immunosuppression.

Grevel J, Napoli KL, Kahan BD.

Transplant Proc. 1990 Jun;22(3):1113-5. No abstract available.

PMID:
2349671
23.

Steady-state concentrations of cyclosporine for therapeutic monitoring.

Grevel J, Napoli KL, Kahan BD.

Transplant Proc. 1990 Jun;22(3):1339-42. No abstract available.

PMID:
2190397
25.
26.

The impact of steady-state cyclosporine concentrations on renal allograft outcome.

Dunn J, Grevel J, Napoli K, Lewis RM, Van Buren CT, Kahan BD.

Transplantation. 1990 Jan;49(1):30-4.

PMID:
2301023
27.

Lipid abnormalities in renal transplant recipients treated with cyclosporine.

Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Dunn J, Goldstein RA, Van Buren CT, Lewis RM, Kahan BD.

Transplant Proc. 1989 Aug;21(4):3670-3. No abstract available.

PMID:
2669278
28.

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.

Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, Van Buren CT, Lewis RM, Kahan BD.

Transplantation. 1989 Jul;48(1):37-43.

PMID:
2665233
29.

Population pharmacokinetic analysis of bisoprolol.

Grevel J, Thomas P, Whiting B.

Clin Pharmacokinet. 1989 Jul;17(1):53-63.

PMID:
2568209
30.

The effect of end-to-side portacaval shunt on cyclosporine pharmacokinetics in rats.

Grevel J, Rigotti P, Citterio F, Plebani M, Kahan BD.

Pharm Res. 1989 Mar;6(3):255-7. No abstract available.

PMID:
2786195
31.

Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients.

Grevel J, Reynolds KL, Rutzky LP, Kahan BD.

J Clin Pharmacol. 1989 Mar;29(3):261-6.

PMID:
2723114
32.

Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction.

Naoumov NV, Tredger JM, Steward CM, O'Grady JG, Grevel J, Niven A, Whiting B, Williams R.

Gut. 1989 Mar;30(3):391-6.

33.
34.

Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy.

Kahan BD, Grevel J.

Transplantation. 1988 Nov;46(5):631-44. Review.

PMID:
3057685
35.

Cyclosporine pharmacokinetics in uremic patients: influence of different assay methods.

Reynolds KL, Grevel J, Gibbons SY, Welsh MS, Rutzky LP, Kahan BD.

Transplant Proc. 1988 Apr;20(2 Suppl 2):462-5. No abstract available.

PMID:
3363649
36.

Influence of biliary T tube clamping on cyclosporine pharmacokinetics in liver transplant recipients.

Tredger JM, Naoumov NV, Steward CM, O'Grady JG, Grevel J, Niven AA, Kelman AW, Whiting B, Williams R.

Transplant Proc. 1988 Apr;20(2 Suppl 2):512-5. No abstract available.

PMID:
3284098
37.

Significance of cyclosporine pharmacokinetics.

Grevel J.

Transplant Proc. 1988 Apr;20(2 Suppl 2):428-34. Review. No abstract available.

PMID:
3284088
38.

Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients.

Gibbons S, Grevel J, Reynolds K, Ried M, Rutzky LP, Kahan BD.

Transplant Proc. 1988 Apr;20(2 Suppl 2):339-44. No abstract available.

PMID:
3284077
39.

Cyclosporine pharmacokinetics and pharmacodynamics after oral administration in the rat.

Didlake RH, Kim EK, Grevel J, Jarolimek L, Kahan BD.

Transplant Proc. 1988 Apr;20(2 Suppl 2):692-5. No abstract available.

PMID:
2966483
40.

Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients.

Grevel J, Whiting B, Kelman AW, Taylor WB, Bateman DN.

Clin Pharmacokinet. 1988 Jan;14(1):52-63.

PMID:
3349725
41.

The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.

Dominiak P, Grevel J, Abisch E, Grobecker H, Dennler HJ, Welzel D.

Eur J Clin Pharmacol. 1988;35(1):53-7.

PMID:
3146506
42.

Kinetic-effect models and their applications.

Grevel J.

Pharm Res. 1987 Apr;4(2):86-91. Review.

PMID:
3334411
43.

The relevance of pharmacokinetics to optimal intravenous anesthesia.

Grevel J, Whiting B.

Anesthesiology. 1987 Jan;66(1):1-2. No abstract available.

PMID:
3800025
44.

Absorption of cyclosporine A after oral dosing.

Grevel J.

Transplant Proc. 1986 Dec;18(6 Suppl 5):9-15.

PMID:
3538574
45.

Pharmacokinetics of high-dose metoclopramide in cancer patients.

McGovern EM, Grevel J, Bryson SM.

Clin Pharmacokinet. 1986 Nov-Dec;11(6):415-24. Review.

PMID:
3542335
46.

Population pharmacokinetics. Theory and clinical application.

Whiting B, Kelman AW, Grevel J.

Clin Pharmacokinet. 1986 Sep-Oct;11(5):387-401. Review.

PMID:
3536257
47.
48.
49.

Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects.

Grevel J, Nüesch E, Abisch E, Kutz K.

Eur J Clin Pharmacol. 1986;31(2):211-6.

PMID:
3803418
50.

Pharmacokinetics, metabolism and interactions of ciclosporin.

Grevel J.

Contrib Nephrol. 1986;51:23-30. Review. No abstract available.

PMID:
3552416

Supplemental Content

Loading ...
Support Center